• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries
    All News
    Headline News
    Press Releases
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    News headline image
    ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Stride, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – LRN
    From The Rosen Law Firm PA
    Via GlobeNewswire
    Tickers LRN
    News headline image
    Balancer Announcement: If You Have Suffered Losses in Balancer Cryptocurrency, You Are Encouraged to Contact The Rosen Law Firm About Your Rights
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    CRMT Investor News: If You Have Suffered Losses in America’s Car-Mart, Inc. (NASDAQ: CRMT), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
    From The Rosen Law Firm PA
    Via GlobeNewswire
    Tickers CRMT
    News headline image
    Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    Tickers FULC
    News headline image
    TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
    From TScan Therapeutics, Inc.
    Via GlobeNewswire
    Tickers TCRX
    News headline image
    DXCM DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages DexCom, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – DXCM
    From The Rosen Law Firm PA
    Via GlobeNewswire
    Tickers DXCM
    News headline image
    BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
    From BioNTech SE
    Via GlobeNewswire
    Tickers BNTX
    News headline image
    ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
    From The Rosen Law Firm PA
    Via GlobeNewswire
    Tickers ALVO
    News headline image
    Remedy's Nutrition® Launches Cyst-Be-Gone™ — Advanced Herbal Formula to Support Natural Cyst & Tissue Wellness
    From Remedy's Nutrition
    Via GlobeNewswire
    News headline image
    Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025
    From Legend Biotech USA Inc.
    Via GlobeNewswire
    Tickers LEGN
    News headline image
    THE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality
    From USA News Group
    Via GlobeNewswire
    Tickers AVAI CSE:GOH GHVNF ONCY TSX-V:VPT VPTDF
    News headline image
    AGL Investor News: If You Have Suffered Losses in agilon health, inc. (NYSE: AGL), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
    From The Rosen Law Firm PA
    Via GlobeNewswire
    Tickers AGL
    News headline image
    Anthony Constantino’s ‘Thank You President Trump’ Album Release To Light Up Fontainebleau LIV Tonight; Hit song “Fight” has over 4 million views in 5 days
    From Sticker Mule
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    Tickers PRLD
    News headline image
    BLUE OWL ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Blue Owl Capital, Inc. and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    CEPTON URGENT ALERT: Bragar Eagel & Squire, P.C. Reminds Cepton Stockholders of Upcoming December 8th Lead Plaintiff Deadline
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    MAREX URGENT DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Marex Stockholders to Contact the Firm Before December 8th Deadline
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Tickers MRX
    News headline image
    ATYR CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds aTyr Investors to Contact the Firm Before December 8th Regarding Their Rights
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Tickers ATYR
    News headline image
    ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages StubHub Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – STUB
    From The Rosen Law Firm PA
    Via GlobeNewswire
    Tickers STUB
    News headline image
    Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting
    From Adaptive Biotechnologies
    Via GlobeNewswire
    Tickers ADPT
    News headline image
    Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company's RXR agonist compound IRX4204 has synergistic efficacy against human
    From Io Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition
    From Arvinas Inc.
    Via GlobeNewswire
    Tickers ARVN
    News headline image
    Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting
    From Beam Therapeutics
    Via GlobeNewswire
    Tickers BEAM
    News headline image
    Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Tickers APTOF TSX:APS
    News headline image
    Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
    From Disc Medicine Inc
    Via GlobeNewswire
    Tickers IRON
    News headline image
    Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    Tickers BCAX
    News headline image
    Cardinal Point Wealth Management Releases New 2025 Cross-Border Retirement Guide for High-Net-Worth Families
    From Cardinal Point Wealth Management, ULC
    Via GlobeNewswire
    News headline image
    Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients
    From Junshi Biosciences
    Via GlobeNewswire
    News headline image
    Cerevance Showcases Positive Phase 2 Results Demonstrating Significant Reduction in OFF Time with Solengepras as an Adjunctive Treatment in Parkinson’s Disease
    From Cerevance, Inc.
    Via GlobeNewswire
    News headline image
    Anika Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors ANIK
    From Kirby McInerney LLP
    Via GlobeNewswire
    Tickers ANIK
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.